OM:CEVI

Stock Analysis Report

Executive Summary

CellaVision AB (publ) develops and sells digital solutions for blood and body fluids analysis in health care services sector in Sweden and internationally.

Snowflake

Fundamentals

Flawless balance sheet with high growth potential.

Share Price & News

How has CellaVision's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-1.0%

CEVI

5.5%

SE Medical Equipment

2.1%

SE Market


1 Year Return

35.2%

CEVI

34.0%

SE Medical Equipment

12.1%

SE Market

Return vs Industry: CEVI exceeded the Swedish Medical Equipment industry which returned 34% over the past year.

Return vs Market: CEVI exceeded the Swedish Market which returned 12.1% over the past year.


Shareholder returns

CEVIIndustryMarket
7 Day-1.0%5.5%2.1%
30 Day-8.0%1.3%1.6%
90 Day-1.0%1.6%3.7%
1 Year35.8%35.2%35.4%34.0%16.8%12.1%
3 Year284.9%275.7%54.9%36.6%32.2%12.4%
5 Year1200.7%1110.1%72.9%44.6%62.8%28.3%

Price Volatility Vs. Market

How volatile is CellaVision's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is CellaVision undervalued compared to its fair value and its price relative to the market?

79.96x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: CEVI (SEK348.5) is trading above our estimate of fair value (SEK277.4)

Significantly Below Fair Value: CEVI is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: CEVI is poor value based on its PE Ratio (80x) compared to the Medical Equipment industry average (44x).

PE vs Market: CEVI is poor value based on its PE Ratio (80x) compared to the Swedish market (16.9x).


Price to Earnings Growth Ratio

PEG Ratio: CEVI is poor value based on its PEG Ratio (4x)


Price to Book Ratio

PB vs Industry: CEVI is overvalued based on its PB Ratio (26.8x) compared to the SE Medical Equipment industry average (4.4x).


Next Steps

Future Growth

How is CellaVision forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

20.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CEVI's forecast earnings growth (20.1% per year) is above the savings rate (0.4%).

Earnings vs Market: CEVI's earnings (20.1% per year) are forecast to grow faster than the Swedish market (9.3% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: CEVI's revenue (19.9% per year) is forecast to grow faster than the Swedish market (4.5% per year).

High Growth Revenue: CEVI's revenue (19.9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: CEVI's Return on Equity is forecast to be high in 3 years time (33.4%)


Next Steps

Past Performance

How has CellaVision performed over the past 5 years?

20.8%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: CEVI's earnings have grown significantly by 20.8% per year over the past 5 years.

Accelerating Growth: CEVI's earnings growth over the past year (54.3%) exceeds its 5-year average (20.8% per year).

Earnings vs Industry: CEVI earnings growth over the past year (54.3%) exceeded the Medical Equipment industry 17.3%.


Return on Equity

High ROE: CEVI's Return on Equity (33.5%) is considered high.


Return on Assets

ROA vs Industry: CEVI has a higher Return on Assets than the Medical Equipment industry average last year.


Return on Capital Employed

ROCE Improving: CEVI's Return on Capital Employed has declined over the past 3 years.


Next Steps

Financial Health

How is CellaVision's financial position?


Financial Position Analysis

Short Term Liabilities: CEVI's short term assets (SEK306.3M) exceeds its short term liabilities (SEK74.4M)

Long Term Liabilities: CEVI's short term assets (306.3M) exceeds its long term liabilities (33.5M)


Debt to Equity History and Analysis

Debt Level: CEVI is debt free.

Reducing Debt: CEVI had no debt 5 years ago.

Debt Coverage: CEVI has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: CEVI has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

Inventory Level: CEVI has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if CEVI's debt is covered by short term assets.


Next Steps

Dividend

What is CellaVision's current dividend yield, its reliability and sustainability?

0.43%

Current Dividend Yield


Dividend Yield vs Market

company0.4%marketbottom25%1.8%markettop25%4.6%industryaverage1.1%forecastin3Years0.6%

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: CEVI's dividend (0.43%) isn’t notable compared to the bottom 25% of dividend payers in the Swedish market (1.81%).

High Dividend: CEVI's dividend (0.43%) is low compared to the top 25% of dividend payers in the Swedish market (4.65%).

Stable Dividend: CEVI is not paying a notable dividend for the Swedish market, therefore no need to check if payments are stable.

Growing Dividend: CEVI is not paying a notable dividend for the Swedish market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: CEVI is not paying a notable dividend for the Swedish market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CEVI's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.


Next Steps

Management

What is the CEO of CellaVision's salary, the management and board of directors tenure and is there insider trading?

4.4yrs

Average board tenure


CEO

Zlatko Rihter (49yo)

4.8yrs

Tenure

0

Mr. Zlatko Rihter has been the Chief Executive Officer and President of CellaVision AB since January 1, 2015. Mr. Rihter joined CellaVision in 2015. He served as an Executive Vice President of Global Sales ...


Board Age and Tenure

4.4yrs

Average Tenure

55yo

Average Age

Experienced Board: CEVI's board of directors are considered experienced (4.4 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Christer Fåhraeus (54yo)

    Founder & Director

    • Tenure: 25.8yrs
    • Compensation: kr193.00k
  • Peter Wilson (52yo)

    Vice President of Global Marketing

    • Tenure: 0yrs
  • Maria Morin (45yo)

    VP of HR & Corporate Communications

    • Tenure: 0yrs
  • Magnus Blixt (53yo)

    Chief Financial Officer

    • Tenure: 6.4yrs
  • Zlatko Rihter (49yo)

    President & CEO

    • Tenure: 4.8yrs
  • Mattias Lundin (51yo)

    Vice President of Global Sales

    • Tenure: 0yrs

Board Members

  • Christer Fåhraeus (54yo)

    Founder & Director

    • Tenure: 25.8yrs
    • Compensation: kr193.00k
  • Anna Bernsten (58yo)

    Director

    • Tenure: 9.5yrs
    • Compensation: kr207.00k
  • Sören Mellstig (68yo)

    Chairman of the Board

    • Tenure: 3.8yrs
    • Compensation: kr494.00k
  • Åsa Hedin (57yo)

    Director

    • Tenure: 4.4yrs
    • Compensation: kr213.00k
  • Niklas Prager (49yo)

    Director

    • Tenure: 5.8yrs
    • Compensation: kr227.00k
  • Stefan Wolf (55yo)

    Director

    • Tenure: 1.4yrs
    • Compensation: kr133.00k
  • Jürgen Riedl (42yo)

    Director

    • Tenure: 1.4yrs
    • Compensation: kr133.00k

Company Information

CellaVision AB (publ)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: CellaVision AB (publ)
  • Ticker: CEVI
  • Exchange: OM
  • Founded: 1994
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: kr8.312b
  • Shares outstanding: 23.85m
  • Website: https://www.cellavision.com

Number of Employees


Location

  • CellaVision AB (publ)
  • Mobilvägen 12
  • Lund
  • Skåne County
  • 223 62
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CEVIOM (OMX Nordic Exchange Stockholm)YesRegistered SharesSESEKMay 2007
CLVS.FOTCPK (Pink Sheets LLC)YesRegistered SharesUSUSDMay 2007
0MR5LSE (London Stock Exchange)YesRegistered SharesGBSEKMay 2007
CEVISBATS-CHIXE (BATS 'Chi-X Europe')YesRegistered SharesGBSEKMay 2007
C26DB (Deutsche Boerse AG)YesRegistered SharesDEEURMay 2007

Biography

CellaVision AB (publ) develops and sells digital solutions for blood and body fluids analysis in health care services sector in Sweden and internationally. It offers analyzers, supplementary software, and  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/20 20:39
End of Day Share Price2019/10/18 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.